14.9 Evidence Behind the Case

Time To Read

5–8 minutes

Date Last Modified

Blood · The Evidence Behind the Case

The acute-phase response as a slow fuse — check our reasoning

This module reads Stina’s chronic labs — reactive thrombocytosis, sterile neutrophilia, years of raised ESR and CRP, and above all serum amyloid A — as one sustained acute-phase response quietly seeding amyloidosis, and holds two findings outside it: a true erythrocytosis on an inappropriate EPO, and an MGUS. Here is what that rests on, and how strong each piece is.

Arrived here from a search?

This page belongs to a teaching case built around familial Mediterranean fever, an IL-1β-driven autoinflammatory disease. If you found it searching a blood finding — persistently raised SAA or CRP, reactive thrombocytosis, sterile neutrophilia, erythrocytosis with an inappropriately high EPO, MGUS in a young adult, it is an evidence-anchored starting point.

1

Each claim, its evidence, and how strong it is

Chart findingThe claim the module makesSupporting evidenceHow strong?
Markers high for years
Chart Clue #14
A sustained acute-phase response is the raw material for future amyloidosis — not “counts a touch high, nothing to chase”.SAA & occult inflammation in asymptomatic FMF (2019) · Acute-phase reactants predict FMF amyloidosis (2007)FMF cohorts
Serum amyloid A
The slow fuse
Liver-made SAA, chronically elevated, is the precursor of AA amyloid; persistent elevation predicts amyloidosis, and colchicine prevents it.SAA in asymptomatic FMF · SAA & amyloidosis risk · EULAR/PReS 2024FMF cohorts + guideline
Reactive thrombocytosis & neutrophilia
During flares
Platelet and neutrophil counts track FMF activity; IL-6 drives reactive thrombopoiesis through thrombopoietin (general mechanism).Acute-phase response in FMF (Ann Rheum Dis 2002) · Hematological markers in FMF (Rheumatol Int 2023) · IL-6 & thrombopoiesis (Blood 2001)FMF cohorts + general mechanism
Erythrocytosis on high EPO
Held open
A true erythrocytosis with an inappropriately elevated EPO, JAK2 negative, sits outside the acute-phase story — a deliberate differential seed, unrelated to FMF.The TEMPI syndrome (Blood 2020 review) · TEMPI syndrome (NEJM 2011)Teaching aside — not FMF
MGUS at 40
Held apart
A monoclonal gammopathy of undetermined significance is a plasma-cell clone, not a product of the liver’s alarm; it is watched and carried to the Immunity module.MGUS natural history (general hematology references)General
Her specific numbers
Module’s own detail
The 2015 panel (Hct 49, RBC 5.6, Hb 16.4, MCV 88; platelets 410/560; WBC 11,800 with 78% neutrophils; ESR 58, CRP 41, SAA 190/38; EPO 44; JAK2 negative; red-cell mass 36; M-protein 0.6 IgG-κ; plasma cells 6%) is this case’s narrative, consistent with the case timeline’s “erythrocytosis, MGUS at 40 by SPEP, SAA, protein gap” — not a published record.The case timeline (this course)Case narrative

Think · not graded

Which rows are FMF cohorts, which are general mechanism, which is a teaching aside deliberately unrelated to FMF, and which is the module’s own detail? Does the reasoning survive if the specific numbers change?

Spot-check your thinking: true or false?

How to read the strength column

Guideline — an expert panel pools many studies into practice recommendations. Trial — patients assigned to a treatment and compared. Cohort — a group of patients measured the same way; good for how often something happens. Case series or review — several patients described together, or the settled background. General mechanism — textbook physiology rather than a study of this disease. Case report — one striking patient; it shows that something can happen, not how often.

Every Evidence page in the course uses the same labels.

2

Lived experience and evidence

A note on validity — from the author

Stina is not a composite. Stina is me. The years of markers dismissed as “a touch high” were mine — and they were not noise; they were a slow fuse burning toward my kidneys. And a hematocrit called dehydration five times was mine too — a loose end I am still holding.

This page holds both truths at once. The lived experience is real; the research support is what earns the case a place in a science course, and the steps that rest on this case’s own narrative are flagged. If you are a clinician who arrived from a patient, treat this as a validated starting point that respects the patient’s experience and then hands you the literature.

From Stina’s diary

The whole case, in her own words, year by year.

Read the diary →

3

Beyond Stina — other reasons a panel reads this way

A reactive thrombocytosis, a raised CRP, a high hematocrit and an M-spike each have a long list of their own. Knowing the neighbours is how a clinician reads six findings as four-plus-two — and then asks what is upstream.

Polycythemia vera

A JAK2-driven marrow making red cells on its own: high hematocrit with a low EPO, often high platelets and white cells too; phlebotomy and aspirin — the primary polycythemia her negative JAK2 and high EPO rule out.

Read on NORD →

Secondary polycythemia with a reason

Altitude, smoking, sleep apnoea, lung or heart disease, a high-affinity hemoglobin: high hematocrit, high EPO, and a cause the oxygen sensor can name.

Read on OpenStax 18.3 →

Essential thrombocythemia

A marrow making platelets on its own (JAK2, CALR, MPL): a count that never settles between flares, with clotting and bleeding risk — the primary thrombocytosis her settling count argues against.

Read on NORD →

Iron deficiency and pernicious anemia

The two filling failures: microcytic hypochromic cells with a low ferritin, or macrocytic cells with hypersegmented neutrophils and no intrinsic factor — Maria and Maude.

Read on NHLBI — Anemia →

Multiple myeloma

What MGUS is watched for: a plasma-cell clone above 10% with CRAB features — calcium, renal failure, anemia, bone lesions — none of which she has.

Read on NIH GARD →

Sepsis and bacterial infection

The acute-phase response with a germ: neutrophilia with bands, high CRP and a high procalcitonin, positive cultures — the pattern hers mimics and lacks.

Read on OpenStax 18.4 →

4

Reliable information — a link library

Rare-disease organizations

NORD — National Organization for Rare Disorders
Plain-language disease reports and patient organizations.

NIH GARD — Genetic and Rare Diseases Information Center
The NIH rare-disease reference, with a live help line.

Orphanet
The European rare-disease encyclopedia; look up a syndrome by its signs.

MedlinePlus Genetics
Condition-by-condition summaries from the National Library of Medicine.

FMF, the acute-phase response and amyloid

MedlinePlus Genetics — Familial Mediterranean Fever
The National Library of Medicine’s condition page.

Amyloidosis Foundation
AA amyloidosis explained for patients and families.

American Society of Hematology — Blood basics
Erythrocytosis, thrombocytosis and MGUS explained for patients.

International Myeloma Foundation — MGUS
What “undetermined significance” means and how it is watched.

NIH Office of Dietary Supplements — Iron
What iron does in red cells, and how much the body needs.

Links checked September 2026.

Next · Module 15

The Heart

Sharp chest pain at 3 a.m. that eased when she leaned forward, a scratchy rub on the stethoscope, and a small effusion on echo. The next module builds the heart and reads recurrent pericarditis as serositis wrapping the sac around it.

Reliable information on rare diseases

NORD · NIH GARD · Orphanet · MedlinePlus Genetics: FMF · FMF & AID Global Association · Autoinflammatory Alliance · Global Genes · Amyloidosis Foundation

Stina has one rare disease. In the United States, about 1 in 10 people live with one of the more than 7,000 known rare diseases. These organizations are where patients, families and clinicians go for trustworthy information.

List of terms